Does rhodiola work as well as antidepressants?
In this 57-patient trial, neither Rhodiola rosea nor sertraline separated from placebo on depression scores. The one clear difference was tolerability: adverse events were reported by 30.0% on Rhodiola versus 63.2% on sertraline and 16.7% on placebo (p=0.012).
Rhodiola rosea has been proposed to affect mood through central biogenic amines and beta-endorphins. In animal and laboratory work it appears to stimulate noradrenalin, serotonin, dopamine, and acetylcholine receptors in brain regions involved in mood, and in vitro it inhibits monoamine oxidase A and B.
What the data show:
- Effectiveness: No statistically significant reductions on HAM-D, BDI, or CGI/C, and no significant difference between groups (p=0.79, p=0.28, p=0.17)
- Odds of improving versus placebo: sertraline 1.90 (95% CI 0.44 to 8.20), Rhodiola 1.39 (95% CI 0.38 to 5.04). Both intervals cross 1
- Tolerability: 30.0% on Rhodiola reported adverse events versus 63.2% on sertraline and 16.7% on placebo (p=0.012)
- Study scope: Randomized, double-blind, placebo-controlled, 12-week proof of concept trial in 57 outpatients with mild to moderate major depressive disorder
A randomized placebo-controlled trial published in Phytomedicine compared Rhodiola rosea extract against sertraline and placebo for major depressive disorder. Rhodiola produced less antidepressant effect than sertraline, and its advantage was in side effects, not symptom relief.
Dr. Kumar’s Take
This is a proof of concept study, and I read it as one. Its purpose was to generate preliminary safety and efficacy data to design a definitive trial, not to settle whether Rhodiola treats depression. With 57 people split three ways over 12 weeks, the study was never powered to detect a modest difference, and it did not detect one: all three arms improved somewhat, none significantly, and the confidence intervals around the odds of improving are wide enough to contain both a real benefit and no benefit at all. I want to be blunt about that, because a wide interval is not quiet evidence of efficacy.
The head-to-head design is still the valuable part. Sertraline is a widely prescribed, well-characterized SSRI, and having a placebo arm alongside both active treatments is more informative than yet another herb-versus-placebo study. The finding I trust from this trial is the safety comparison, which did reach statistical significance. Rhodiola was better tolerated. Whether it works is a question this study leaves open.
Study Snapshot
This randomized, double-blind, placebo-controlled trial enrolled outpatients with mild to moderate major depressive disorder and assigned them to 12 weeks of standardized Rhodiola rosea extract, sertraline, or placebo. Changes over time in Hamilton Depression Rating (HAM-D), Beck Depression Inventory (BDI), and Clinical Global Impression Change (CGI/C) scores were compared among groups using mixed-effects models. The trial was approved by the University of Pennsylvania institutional review board, run under Good Clinical Practice guidelines, and monitored by an independent data and safety monitoring board.
Results in Real Numbers
Fifty-seven subjects were randomized to 12 weeks of standardized Rhodiola rosea extract, sertraline, or placebo. Modest reductions in HAM-D, BDI, and CGI/C scores were observed in all three treatment conditions, but the reductions were statistically non-significant and there was no significant difference between groups (p=0.79, p=0.28, and p=0.17, respectively).
The decline in HAM-D scores was greater for sertraline (-8.2, 95% CI -12.7 to -3.6) than for Rhodiola (-5.1, 95% CI -8.8 to -1.3) or placebo (-4.6, 95% CI -8.6 to -0.6). The odds of improving versus placebo were 1.90 (95% CI 0.44 to 8.20) for sertraline and 1.39 (95% CI 0.38 to 5.04) for Rhodiola. Both confidence intervals include 1, so neither active treatment was shown to beat placebo.
Adverse events told a different story. More subjects on sertraline reported adverse events (63.2%) than on Rhodiola (30.0%) or placebo (16.7%), and that difference was statistically significant (p=0.012). The authors concluded that although Rhodiola produced less antidepressant effect than sertraline, it resulted in significantly fewer adverse events and was better tolerated, which may give it a more favorable risk to benefit ratio in mild to moderate depression.
Who Benefits Most
This trial does not identify a group for whom Rhodiola relieves depression, because it did not demonstrate that Rhodiola relieves depression. What it does support is a narrower point about tolerability.
People with mild to moderate depression who are weighing side effects against the benefits of conventional antidepressants may find the tolerability data relevant to that decision. The paper notes that many individuals with milder depressive symptoms do exactly this weighing, and that depressive symptoms are among the most common reasons people cite for choosing alternative therapy. Anyone considering Rhodiola on that basis should understand they are choosing a treatment with a better side effect profile in this trial and unproven antidepressant benefit.
Safety, Limits, and Caveats
Rhodiola was better tolerated than sertraline here, but tolerability is not efficacy. The primary limitation of this study is its size and purpose: 57 subjects across three arms in a proof of concept trial designed to inform a larger definitive study. Non-significant results in a trial this small do not prove Rhodiola is ineffective, and they do not show it works either.
Sertraline produced the largest decline in HAM-D scores of the three arms, though the between-group comparison was not significant. For anyone with depression severe enough to need reliable treatment, this trial gives no reason to choose Rhodiola over an antidepressant with an established evidence base.
Practical Takeaways
- Treat Rhodiola rosea as unproven for depression based on this trial, not as a demonstrated alternative to an SSRI
- If side effects are your main obstacle to antidepressant treatment, the tolerability difference here is real and statistically significant, and worth raising with your physician
- Do not stop or replace a prescribed antidepressant on the strength of a 57-person proof of concept study
- Discuss Rhodiola use with your healthcare providers, especially if you take other medications or supplements
- Watch for larger trials. The authors ran this study specifically to inform the design of a definitive one
What This Means for Depression Treatment
The honest summary of this trial is that a head-to-head comparison of Rhodiola rosea, sertraline, and placebo found no significant symptom difference between any of the three, and a significant difference in adverse events favoring Rhodiola and placebo over sertraline. That is a finding about safety, not about efficacy.
I think this is still a useful contribution. Three-arm designs that put an herbal preparation against both an active drug and a placebo are rare, and they are the only way to learn whether an alternative therapy earns its place. This one produced a signal worth chasing in a properly powered trial, which is precisely what a proof of concept study is for.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
How does Rhodiola rosea compare to sertraline for depression?
Sertraline produced a larger decline in HAM-D scores, but the difference between groups was not statistically significant. Rhodiola was significantly better tolerated, with adverse events in 30.0% of subjects versus 63.2% on sertraline.
Is Rhodiola rosea safe for depression treatment?
In this trial Rhodiola was better tolerated than sertraline, with significantly fewer adverse events reported. Individual responses vary, and 12 weeks in 57 people is a limited basis for broad safety conclusions.
Can Rhodiola rosea replace prescription antidepressants?
This trial does not support that. Rhodiola produced less antidepressant effect than sertraline and did not separate from placebo. Treatment decisions belong with your healthcare provider and should account for depression severity and prior response.
Bottom Line
In this randomized placebo-controlled trial, Rhodiola rosea did not show significant antidepressant efficacy, and it produced less antidepressant effect than sertraline. What it did show was significantly better tolerability: 30.0% of subjects reported adverse events on Rhodiola versus 63.2% on sertraline.
